TheodoreLCrandallMD

PubMed

• 13 citations
  Phase II Study of Irinotecan and Cetuximab Given Every 2 Weeks as Second-Line Therapy for Advanced Colorectal Cancer
  Benedito A. Carneiro, Ramesh K. Ramanathan, Smitha S. Krishnamurthi, Barry C. Lembersky, Ronald G. Stoller, Stewart L. Lancaster, Theodore L. Crandall, Amy Schmotzer, ...> ;Clinical Colorectal Cancer. 2012 Mar 1
• 3 citations
  A phase I/II study of capecitabine given on a week on/week off schedule combined with bevacizumab and oxaliplatin for patients with untreated advanced colorectal cancer
  Rajesh Sehgal, Barry C. Lembersky, K. K. Rajasenan, Theodore L. Crandall, Edward P. Balaban, Patrick Kane, Amy Schmotzer, Herbert J. Zeh, Douglas M. Potter, Ramesh K. ...> ;Clinical Colorectal Cancer. 2011 Jun 1
• Phase II study of biweekly cetuximab (C) and irinotecan (I) as a second-line regimen for metastatic colorectal cancer (mCRC).
  Carneiro BA, Bahary N, Lembersky B, Fakih M, Krishnamurthi SS, Lancaster S, Pinkerton R, Crandall T, Potter D, Ramanathan RK> ;J. Clin. Oncol.. 2009-05-20
• Phase II study of bevacizumab (BEV), weekly (wkly) intermittent capecitabine (Cap), and oxaliplatin (Ox) on an every-2-week schedule for patients (Pts) with untreated ...
  Lembersky BC, Sehgal R, Rajasenan KK, Crandall TL, Balaban EP, Pinkerton RA, Kane P, Potter DM, Kinney C, Ramanathan RK> ;J. Clin. Oncol.. 2008-05-20
• Join now to see all